Stock itci.

The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY. ITCI - Intra-Cellular Therapies Inc - Stock screener for investors and traders, financial visualizations.Intra-Cellular Therapeutics ITCI incurred a loss of 45 cents per share in fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The reported loss per share is also ...2 thg 11, 2023 ... ... stock report on ITCI at https://www.zacks.com/ap/ITCI. Advertisement. Sign up for the Daily Brief. Our free, fast, and fun briefing on the ...0001193125-20-214163.txt : 20200810 0001193125-20-214163.hdr.sgml : 20200810 20200810081722 ACCESSION NUMBER: 0001193125-20-214163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTHave the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...

Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and ...

IntraCellular Therapies (ITCI) (Delayed Data from NSDQ) $61.37 USD +1.94 (3.26%) Updated Nov 30, 2023 04:00 PM ET After-Market: $61.37 0.00 (0.00%) 4:48 PM …0001193125-21-155623.txt : 20210510 0001193125-21-155623.hdr.sgml : 20210510 20210510073115 ACCESSION NUMBER: 0001193125-21-155623 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT

Intracellular Th stock price (ITCI) NASDAQ: ITCI. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Intracellular Th stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock.Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.Stock Price Statistics. The stock price has increased by +13.77% in the last 52 weeks. The beta is 1.04, so ITCI's price volatility has been similar to the market average.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...The stock of the company was up 16% on Tuesday following the news. In the past year, shares of Intra-Cellular have declined 7.6% compared with the industry ’s 15.9% fall. In the label-expanding ...

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research …

Latest Intra-Cellular Therapies News: View ITCI news and discuss market sentiment with the investor community on Public.com.

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …The company increased its Caplyta net product sales in the range of $445-$465 million (previously $430-$455 million) for the full-year 2023. Intra-Cellular, however, maintained its full-year 2023 ...Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ...(2017-09-27 | NDAQ:ITCI) Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic.Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold.

ITCI Profile Stock Screener Earnings Calendar Sectors Nasdaq | ITCI U.S.: Nasdaq Intra-Cellular Therapies Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023...Mar 28, 2023 · 04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ... ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...Mar 29, 2023 · ITCI stock shot up to approximately $55 per share after the success of study 403. There is some overhead supply to work through to reach new all-time highs and continued strong sales momentum and ... Oct 9, 2023 · Intra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...

A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...View the latest Intra-Cellular Therapies Inc. (ITCI) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Intra-Cellular Therapies had revenue of $420.14M in the twelve months ending September 30, 2023, with 123.34% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $126.17M with 75.56% year-over-year growth. In the year 2022, Intra-Cellular Therapies had annual revenue of $250.31M with 198.69% growth.Mar. 1, 2023, 07:55 AM. In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Intra-Cellular Therapies ( ITCI – Research Report ), with a price target ...1.05%. ¥6.6T. VST Industries Ltd. 0.49%. ₹52.52B. ITC | Complete ITC Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ...Oct 26, 2023 · Intra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend. seekingalpha.com - August 12 at 10:29 AM. GW&K Investment Management LLC Purchases 302,685 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 11 at 7:34 PM. Barclays PLC Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) marketbeat.com - August 8 at 6:11 AM.Tsai is hardly the only bull on this stock; ITCI has a unanimous Strong Buy consensus rating supported by 9 analyst reviews. The average price target of $68.67 gives a 12% upside potential from the current share price of $61.05. (See ITCI stock analysis on TipRanks)CAPLYTA is a prescription medication used in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression). CAPLYTA can be taken alone or with the medicines lithium or valproate for bipolar depression. It is not known if CAPLYTA is safe and effective in children.

The firm decreased its portfolio allocation in ITCI by 99.89% over the last quarter. ITOT - iShares Core S&P Total U.S. Stock Market ETF holds 89K shares representing 0.09% ownership of the company.

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, …

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, …Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... Ticker Symbol: ITCI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001567514: CUSIP Number: 46116X101: ISIN Number: US46116X1019The stock is down more than 12% over the past 12 months but up more than 2% so far in 2023. ... (ITCI) Q3 2021 Earnings Call Transcript. Why Intra-Cellular Therapies Was Weak This Week.The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023.Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting ...The 13 analysts offering 1 year price forecasts for ITCI have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to ITCI in the past 3 months.View Valuation. Research Intra-Cellular Therapies' (Nasdaq:ITCI) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, …Nov 28, 2023 · Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023. On November 2, 2023, Intra-Cellular Therapies Inc (ITCI) stock had a median target price of $76.00, according to 13 analysts offering 12-month price forecasts. The high estimate for the stock was $100.00, while the low estimate was $59.00. The consensus among 14 investment analysts was to buy stock in Intra-Cellular Therapies Inc.

ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …Instagram:https://instagram. top precious metals dealerscheap stocks under dollar10microsoft dividend dateoil refineries in the us The average twelve-month price prediction for Intra-Cellular Therapies is $78.67 with a high price target of $101.00 and a low price target of $62.00. Learn more on ITCI's analyst rating history. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?Nov 2, 2023 · The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average for the last 20 days is -0.20% for ITCI stock ... dow jones completion tsm indextop stock screeners Track Intra-Cellular Therapies Inc (ITCI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ... how to start trading in crypto Referenced Symbols. Shares of Intra-Cellular Therapies Inc. ITCI, +3.26% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive ...Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.